<DOC>
	<DOC>NCT00414011</DOC>
	<brief_summary>The purpose of this study is a prospective,double-blinded, randomized trial to compare the rate of healing following PRK after the use of two commercially available 4th generation fluoroquinolones, moxifloxacin and gatifloxacin.</brief_summary>
	<brief_title>Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)</brief_title>
	<detailed_description />
	<mesh_term>Gatifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Manifest refraction spherical equivalent (MSE) of up to 6.00 diopters (D) at the spectacle plane with refractive cylinder up to 3.00D. Concurrent topical or systemic medications that may impair healing including corticosteroids, antimetabolites, isotretinoin, amiodarone hydrochloride and/ or sumatripin. Patients with known sensitivity or inappropriate responsiveness to any of the medications used in the postoperative course. Anterior basement membrane dystrophy. History of recurrent epithelial erosion. Significant dry eye (symptomatic sith Schirmer &lt;5mm at 5 minutes) Other corneal epithelial disorder or healing abnormality</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Removal of corneal epithelium followed by excimer laser treatment during prk</keyword>
</DOC>